Narawitch Sompornpailin
1
* , MSc, MD ;
Thiti Susiriwatananont
1
* , MSc, MD ;
Virote Sriuranpong
1
, MD, PhD ;
Suebpong Tanasanvimon
1
, MSc, MD ;
Chanida Vinayanuwattikun
1
, MD, PhD ;
Piyada Sitthideatphaiboon
1
, MSc, MD ;
Nattaya Poovorawan
1
, MSc, MD ;
Nattaya Teeyapun
1
, MSc, MD ;
Nicha Zungsontiporn
1
, MSc, MD ;
Nussara Pakvisal
1
, MSc, MD ;
Poonnakarn Panjasriprakarn
2
, MD ;
Bussaba Trakarnsanga
3
, PharmD ;
Napa Parinyanitikul
1
, MSc, MD
1
Division of Medical Oncology, Department of Medicine, Faculty of Medicine, Chulalongkorn University & The King Chulalongkorn Memorial Hospital, Bangkok, Thailand
2
Division of Neurology, Department of Medicine, Faculty of Medicine, Chulalongkorn University & The King Chulalongkorn Memorial Hospital, Bangkok, Thailand
3
Pharmacy Department, King Chulalongkorn Memorial Hospital, Bangkok, Thailand
*these authors contributed equally
Corresponding Author:
-
Napa Parinyanitikul, MSc, MD
-
Division of Medical Oncology, Department of Medicine
-
Faculty of Medicine
-
Chulalongkorn University & The King Chulalongkorn Memorial Hospital
-
1873 Rama 4 Rd. Pathumwan
-
Bangkok 10330
-
Thailand
-
Phone:
66 02256 4000
-
Email: napa.p@chula.ac.th